Microscopic Colitis: Is Vedolizumab An Option?
Due to the relatively high relapse rate and need for additional therapies, current research is being done on the use of Vedolizumab for the treatment of microscopic colitis.
Ulcerative Colitis
Upadacitinib Meets Endpoints in Ulcerative Colitis Maintenance Trial
A significantly greater proportion of patients treated with upadacitinib 15mg and 30mg achieved clinical remission at week 52 compared with those receiving placebo.
Zeposia Approved for Moderately to Severely Active Ulcerative Colitis
The FDA has approved Zeposia® (ozanimod) for moderately to severely active ulcerative colitis in adults.
Marijuana and IBD: Challenging Decisions
Though patient use of cannabinoids for the treatment of IBD has increased, clinical decision making on whether to formally recommend it as treatment remains difficult.
Fecal DPP-4 Level May Be Biomarker for Inflammatory Bowel Disease
Researchers aimed to better elucidate the role of fDPP-4 levels as a biomarker of IBD activity and to correlate it with certain clinical parameters.
HIV and Inflammatory Bowel Disease: A Unique Patient Population
The authors review gut dysfunction and microbiota changes during HIV infection and IBD and discuss how they may induce a dysfunctional mucosal barrier, dysbiosis, and changes on the cellular level, including monocytes, macrophages, and dendritic cells.
- Loading...
Loading...
Next post in Medicine
Loading... 
Loading...